|
|
Article: MacroGenics Advancing MAb Program With $45M Series C.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Working to finalize the protocol for a potentially pivotal trial of its anti-CD3 antibody for diabetes, MacroGenics Inc. raised $45 million in a Series C round.
"It's not the easiest market right now, and we wore out a lot of shoe leather," said Nelson Campbell, chief financial officer of Rockville, Md.-based MacroGenics, crediting the company's "strong investor base," as well as "our exciting CD3 molecule, which has been a good catalyst for us, as well."
The biggest chunk of the proceeds will go toward the anti-CD3 monoclonal antibody program, which is heading into a Phase II/III study in Type I diabetes expected to begin later ...
Related newspaper, magazine, and journal articles:
|
|
Article: MacroGenics Acquires Raven Biotechnologies.
PR Newswire;
July 17, 2008 ;
700+ words
... ... in Cancer Stem Cell Biology Enhances MacroGenics' Oncology Capabilities and Complements ... Md., July 17 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology ... cell biology is highly complementary to MacroGenics' proprietary Fc-optimization and ...
|
|